Table 2.
Overview of clinical trials showing selected chemotherapeutics, indication, and association between SLC transporter expression level and therapy response.
| Chemotherapeutic Alone or in Combination (Administration) | Tumor Indication | Transporter, Expression Level (Quality of Measure) | Response to Treatment (Defined Criteria) | Study Design and Patient Number |
|---|---|---|---|---|
| Cisplatin (i.v.) | Head and neck squamous cell carcinoma | OCT3, high (protein) | Higher 2-year survival rate | Retrospective, 42 patients [52] |
| Cytarabine (i.v.) | AML | OCTN1, high (mRNA) | Improved event-free and overall survival (Hazard ratios) | Retrospective, 172 patients [53] |
| 5-FU (i.v.) | Colorectal cancer | OAT2, high (protein) | Good histological response | Pre-treatment biopsy, 45 patients [54] |
| FOLFOX (i.v.) | Metastatic colorectal cancer | OAT2, high (protein) | Good objective tumor response (RECIST) | Retrospective, 90 patients [55] |
| OCT2, high (protein) | Longer progression-free survival (less radiological progression or death) | Retrospective, 90 patients [55] | ||
| OCT3, high (protein) | Non-respond to therapy (cancer recurrence within one year) | Retrospective, 31 patients [56] | ||
| Irinotecan (i.v.) | Metastatic colorectal cancer and advanced/metastatic pancreatic cancer | OATP1B3, high (protein) | Reduced progression-free survival (reduced time from initiation of irinotecan-based chemotherapy to the date of progression, death, last contact, or censor date) | Prospective, 127 patients [38] |
| Oxaliplatin (i.v.) | Metastatic colorectal cancer | OCT2, high (protein) | Longer progression-free survival (longer period from the start of first-line chemotherapy until the first evidence of radiological progression or death) | Retrospective, 80 patients [57] |
| Sorafenib (p.o.) | Hepatocellular carcinoma | OCT1 (mRNA) | Positive association with survival (Hazard ratios) | Retrospective, 60 patients [30] |
| Hepatocellular carcinoma | OCT1, expression at the plasma membrane (protein) | Longer overall survival | Retrospective, 39 patients [31] | |
| Anthracycline and taxane (i.v.) | Breast cancer | OATP1A2, OCT6, high expression of both (protein) | Pathologic good and complete response | Retrospective, 124 patients [58] |
AML, acute myeloid leukemia; 5-FU, 5-fluorouracil; FOLFOX, 5-FU/leucovorin/oxaliplatin; RECIST, response evaluation criteria for solid tumors.